APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Tubulin Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cancer Tubulin Inhibitors Industry Research Report 2026

22 December 2025121 pages

Choose your research edition.

Industry ResearchCancer Tubulin Inhibitors Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Tubulin Inhibitors Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Cancer Tubulin Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Tubulin Inhibitors Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Tubulin Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cancer Tubulin Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cancer Tubulin Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cancer Tubulin Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cancer Tubulin Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cancer Tubulin Inhibitors include Abraxis Biosciences, Agensys, Celgene, Eagle Pharmaceuticals, Endocyte, Genentech, Immunogen, Modra Pharmaceuticals and Pierre Fabre, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cancer Tubulin Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cancer Tubulin Inhibitors Market by Company

Abraxis Biosciences

Agensys

Celgene

Eagle Pharmaceuticals

Endocyte

Genentech

Immunogen

Modra Pharmaceuticals

Pierre Fabre

Sanofi-Aventis

Seattle Genetics

Tocris Bioscience

Amgen

Roche

Cancer Tubulin Inhibitors Segment by Type

Trastuzumab Emtansine

Cabazitaxel

Docetaxel

Brentuximab Vedotin

Abraxane

Cancer Tubulin Inhibitors Segment by Application

Breast Cancer

Prostate Cancer

Ovarian Cancer

Colorectal Cancer

Non Small Cell Lung Cancer

Cancer Tubulin Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Tubulin Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Tubulin Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Tubulin Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cancer Tubulin Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cancer Tubulin Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cancer Tubulin Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cancer Tubulin Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cancer Tubulin Inhibitors Sales (k units) of Manufacturers (2021-2026) Table 7. Global Cancer Tubulin Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cancer Tubulin Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Cancer Tubulin Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cancer Tubulin Inhibitors Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Cancer Tubulin Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cancer Tubulin Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cancer Tubulin Inhibitors, Product Type & Application Table 14. Global Cancer Tubulin Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cancer Tubulin Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abraxis Biosciences Company Information Table 19. Abraxis Biosciences Business Overview Table 20. Abraxis Biosciences Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Abraxis Biosciences Cancer Tubulin Inhibitors Product Portfolio Table 22. Abraxis Biosciences Recent Developments Table 23. Agensys Company Information Table 24. Agensys Business Overview Table 25. Agensys Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Agensys Cancer Tubulin Inhibitors Product Portfolio Table 27. Agensys Recent Developments Table 28. Celgene Company Information Table 29. Celgene Business Overview Table 30. Celgene Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Celgene Cancer Tubulin Inhibitors Product Portfolio Table 32. Celgene Recent Developments Table 33. Eagle Pharmaceuticals Company Information Table 34. Eagle Pharmaceuticals Business Overview Table 35. Eagle Pharmaceuticals Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Eagle Pharmaceuticals Cancer Tubulin Inhibitors Product Portfolio Table 37. Eagle Pharmaceuticals Recent Developments Table 38. Endocyte Company Information Table 39. Endocyte Business Overview Table 40. Endocyte Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Endocyte Cancer Tubulin Inhibitors Product Portfolio Table 42. Endocyte Recent Developments Table 43. Genentech Company Information Table 44. Genentech Business Overview Table 45. Genentech Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Genentech Cancer Tubulin Inhibitors Product Portfolio Table 47. Genentech Recent Developments Table 48. Immunogen Company Information Table 49. Immunogen Business Overview Table 50. Immunogen Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Immunogen Cancer Tubulin Inhibitors Product Portfolio Table 52. Immunogen Recent Developments Table 53. Modra Pharmaceuticals Company Information Table 54. Modra Pharmaceuticals Business Overview Table 55. Modra Pharmaceuticals Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Modra Pharmaceuticals Cancer Tubulin Inhibitors Product Portfolio Table 57. Modra Pharmaceuticals Recent Developments Table 58. Pierre Fabre Company Information Table 59. Pierre Fabre Business Overview Table 60. Pierre Fabre Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Pierre Fabre Cancer Tubulin Inhibitors Product Portfolio Table 62. Pierre Fabre Recent Developments Table 63. Sanofi-Aventis Company Information Table 64. Sanofi-Aventis Business Overview Table 65. Sanofi-Aventis Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Sanofi-Aventis Cancer Tubulin Inhibitors Product Portfolio Table 67. Sanofi-Aventis Recent Developments Table 68. Seattle Genetics Company Information Table 69. Seattle Genetics Business Overview Table 70. Seattle Genetics Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Seattle Genetics Cancer Tubulin Inhibitors Product Portfolio Table 72. Seattle Genetics Recent Developments Table 73. Tocris Bioscience Company Information Table 74. Tocris Bioscience Business Overview Table 75. Tocris Bioscience Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Tocris Bioscience Cancer Tubulin Inhibitors Product Portfolio Table 77. Tocris Bioscience Recent Developments Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Amgen Cancer Tubulin Inhibitors Product Portfolio Table 82. Amgen Recent Developments Table 83. Roche Company Information Table 84. Roche Business Overview Table 85. Roche Cancer Tubulin Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Roche Cancer Tubulin Inhibitors Product Portfolio Table 87. Roche Recent Developments Table 88. Global Cancer Tubulin Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Cancer Tubulin Inhibitors Sales by Region (2021-2026) & (k units) Table 90. Global Cancer Tubulin Inhibitors Sales Market Share by Region (2021-2026) Table 91. Global Cancer Tubulin Inhibitors Sales by Region (2027-2032) & (k units) Table 92. Global Cancer Tubulin Inhibitors Sales Market Share by Region (2027-2032) Table 93. Global Cancer Tubulin Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Cancer Tubulin Inhibitors Revenue Market Share by Region (2021-2026) Table 95. Global Cancer Tubulin Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Cancer Tubulin Inhibitors Revenue Market Share by Region (2027-2032) Table 97. North America Cancer Tubulin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Cancer Tubulin Inhibitors Sales by Country (2021-2026) & (k units) Table 99. North America Cancer Tubulin Inhibitors Sales by Country (2027-2032) & (k units) Table 100. North America Cancer Tubulin Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Cancer Tubulin Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Cancer Tubulin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Cancer Tubulin Inhibitors Sales by Country (2021-2026) & (k units) Table 104. Europe Cancer Tubulin Inhibitors Sales by Country (2027-2032) & (k units) Table 105. Europe Cancer Tubulin Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Cancer Tubulin Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Cancer Tubulin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Cancer Tubulin Inhibitors Sales by Country (2021-2026) & (k units) Table 109. Asia Pacific Cancer Tubulin Inhibitors Sales by Country (2027-2032) & (k units) Table 110. Asia Pacific Cancer Tubulin Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Cancer Tubulin Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Cancer Tubulin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Cancer Tubulin Inhibitors Sales by Country (2021-2026) & (k units) Table 114. South America Cancer Tubulin Inhibitors Sales by Country (2027-2032) & (k units) Table 115. South America Cancer Tubulin Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Cancer Tubulin Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Cancer Tubulin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Cancer Tubulin Inhibitors Sales by Country (2021-2026) & (k units) Table 119. Middle East and Africa Cancer Tubulin Inhibitors Sales by Country (2027-2032) & (k units) Table 120. Middle East and Africa Cancer Tubulin Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Cancer Tubulin Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Cancer Tubulin Inhibitors Sales by Type (2021-2026) & (k units) Table 123. Global Cancer Tubulin Inhibitors Sales by Type (2027-2032) & (k units) Table 124. Global Cancer Tubulin Inhibitors Sales Market Share by Type (2021-2026) Table 125. Global Cancer Tubulin Inhibitors Sales Market Share by Type (2027-2032) Table 126. Global Cancer Tubulin Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Cancer Tubulin Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Cancer Tubulin Inhibitors Revenue Market Share by Type (2021-2026) Table 129. Global Cancer Tubulin Inhibitors Revenue Market Share by Type (2027-2032) Table 130. Global Cancer Tubulin Inhibitors Price by Type (2021-2026) & (US$/unit) Table 131. Global Cancer Tubulin Inhibitors Price by Type (2027-2032) & (US$/unit) Table 132. Global Cancer Tubulin Inhibitors Sales by Application (2021-2026) & (k units) Table 133. Global Cancer Tubulin Inhibitors Sales by Application (2027-2032) & (k units) Table 134. Global Cancer Tubulin Inhibitors Sales Market Share by Application (2021-2026) Table 135. Global Cancer Tubulin Inhibitors Sales Market Share by Application (2027-2032) Table 136. Global Cancer Tubulin Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Cancer Tubulin Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Cancer Tubulin Inhibitors Revenue Market Share by Application (2021-2026) Table 139. Global Cancer Tubulin Inhibitors Revenue Market Share by Application (2027-2032) Table 140. Global Cancer Tubulin Inhibitors Price by Application (2021-2026) & (US$/unit) Table 141. Global Cancer Tubulin Inhibitors Price by Application (2027-2032) & (US$/unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Cancer Tubulin Inhibitors Distributors List Table 145. Cancer Tubulin Inhibitors Customers List Table 146. Cancer Tubulin Inhibitors Industry Trends Table 147. Cancer Tubulin Inhibitors Industry Drivers Table 148. Cancer Tubulin Inhibitors Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cancer Tubulin Inhibitors Product Image Figure 5. Global Cancer Tubulin Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cancer Tubulin Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Cancer Tubulin Inhibitors Sales (2021-2032) & (k units) Figure 8. Global Cancer Tubulin Inhibitors Average Price (US$/unit) & (2021-2032) Figure 9. Trastuzumab Emtansine Product Image Figure 10. Cabazitaxel Product Image Figure 11. Docetaxel Product Image Figure 12. Brentuximab Vedotin Product Image Figure 13. Abraxane Product Image Figure 14. Breast Cancer Product Image Figure 15. Prostate Cancer Product Image Figure 16. Ovarian Cancer Product Image Figure 17. Colorectal Cancer Product Image Figure 18. Non Small Cell Lung Cancer Product Image Figure 19. Global Cancer Tubulin Inhibitors Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Cancer Tubulin Inhibitors, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Cancer Tubulin Inhibitors Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Cancer Tubulin Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Cancer Tubulin Inhibitors Sales by Region in 2025 Figure 25. Global Cancer Tubulin Inhibitors Revenue by Region in 2025 Figure 26. North America Cancer Tubulin Inhibitors Market Size by Country in 2025 Figure 27. North America Cancer Tubulin Inhibitors Sales Market Share by Country (2021-2032) Figure 28. North America Cancer Tubulin Inhibitors Revenue Market Share by Country (2021-2032) Figure 29. United States Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Cancer Tubulin Inhibitors Market Size by Country in 2025 Figure 33. Europe Cancer Tubulin Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Europe Cancer Tubulin Inhibitors Revenue Market Share by Country (2021-2032) Figure 35. Germany Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Cancer Tubulin Inhibitors Market Size by Country in 2025 Figure 46. Asia Pacific Cancer Tubulin Inhibitors Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Cancer Tubulin Inhibitors Revenue Market Share by Country (2021-2032) Figure 48. China Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Cancer Tubulin Inhibitors Market Size by Country in 2025 Figure 57. South America Cancer Tubulin Inhibitors Sales Market Share by Country (2021-2032) Figure 58. South America Cancer Tubulin Inhibitors Revenue Market Share by Country (2021-2032) Figure 59. Brazil Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Cancer Tubulin Inhibitors Market Size by Country in 2025 Figure 63. Middle East and Africa Cancer Tubulin Inhibitors Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Cancer Tubulin Inhibitors Revenue Market Share by Country (2021-2032) Figure 65. Egypt Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Cancer Tubulin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Cancer Tubulin Inhibitors Sales Market Share by Type (2021-2032) Figure 71. Global Cancer Tubulin Inhibitors Revenue Market Share by Type (2021-2032) Figure 72. Global Cancer Tubulin Inhibitors Price (US$/unit) by Type (2021-2032) Figure 73. Global Cancer Tubulin Inhibitors Sales Market Share by Application (2021-2032) Figure 74. Global Cancer Tubulin Inhibitors Revenue Market Share by Application (2021-2032) Figure 75. Global Cancer Tubulin Inhibitors Price (US$/unit) by Application (2021-2032) Figure 76. Cancer Tubulin Inhibitors Value Chain Figure 77. Cancer Tubulin Inhibitors Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Cancer Tubulin Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Trastuzumab Emtansine
  • Cabazitaxel
  • Docetaxel
  • Brentuximab Vedotin
  • Abraxane
Applications
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Non Small Cell Lung Cancer
Companies covered
  • Abraxis Biosciences
  • Agensys
  • Celgene
  • Eagle Pharmaceuticals
  • Endocyte
  • Genentech
  • Immunogen
  • Modra Pharmaceuticals
  • Pierre Fabre
  • Sanofi-Aventis
  • Seattle Genetics
  • Tocris Bioscience
  • Amgen
  • Roche

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cancer Tubulin Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Cancer Tubulin Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Cancer Tubulin Inhibitors Market Average Price (2021-2032)
  6. 2.3 Cancer Tubulin Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Trastuzumab Emtansine
  9. 2.3.3 Cabazitaxel
  10. 2.3.4 Docetaxel
  11. 2.3.5 Brentuximab Vedotin
  12. 2.3.6 Abraxane
  13. 2.4 Cancer Tubulin Inhibitors by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Breast Cancer
  16. 2.4.3 Prostate Cancer
  17. 2.4.4 Ovarian Cancer
  18. 2.4.5 Colorectal Cancer
  19. 2.4.6 Non Small Cell Lung Cancer
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cancer Tubulin Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cancer Tubulin Inhibitors Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Cancer Tubulin Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cancer Tubulin Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cancer Tubulin Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cancer Tubulin Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cancer Tubulin Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Cancer Tubulin Inhibitors, Established Date
  9. 3.9 Global Cancer Tubulin Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abraxis Biosciences
  2. 4.1.1 Abraxis Biosciences Company Information
  3. 4.1.2 Abraxis Biosciences Business Overview
  4. 4.1.3 Abraxis Biosciences Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abraxis Biosciences Cancer Tubulin Inhibitors Product Portfolio
  6. 4.1.5 Abraxis Biosciences Recent Developments
  7. 4.2 Agensys
  8. 4.2.1 Agensys Company Information
  9. 4.2.2 Agensys Business Overview
  10. 4.2.3 Agensys Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Agensys Cancer Tubulin Inhibitors Product Portfolio
  12. 4.2.5 Agensys Recent Developments
  13. 4.3 Celgene
  14. 4.3.1 Celgene Company Information
  15. 4.3.2 Celgene Business Overview
  16. 4.3.3 Celgene Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Celgene Cancer Tubulin Inhibitors Product Portfolio
  18. 4.3.5 Celgene Recent Developments
  19. 4.4 Eagle Pharmaceuticals
  20. 4.4.1 Eagle Pharmaceuticals Company Information
  21. 4.4.2 Eagle Pharmaceuticals Business Overview
  22. 4.4.3 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Product Portfolio
  24. 4.4.5 Eagle Pharmaceuticals Recent Developments
  25. 4.5 Endocyte
  26. 4.5.1 Endocyte Company Information
  27. 4.5.2 Endocyte Business Overview
  28. 4.5.3 Endocyte Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Endocyte Cancer Tubulin Inhibitors Product Portfolio
  30. 4.5.5 Endocyte Recent Developments
  31. 4.6 Genentech
  32. 4.6.1 Genentech Company Information
  33. 4.6.2 Genentech Business Overview
  34. 4.6.3 Genentech Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Genentech Cancer Tubulin Inhibitors Product Portfolio
  36. 4.6.5 Genentech Recent Developments
  37. 4.7 Immunogen
  38. 4.7.1 Immunogen Company Information
  39. 4.7.2 Immunogen Business Overview
  40. 4.7.3 Immunogen Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Immunogen Cancer Tubulin Inhibitors Product Portfolio
  42. 4.7.5 Immunogen Recent Developments
  43. 4.8 Modra Pharmaceuticals
  44. 4.8.1 Modra Pharmaceuticals Company Information
  45. 4.8.2 Modra Pharmaceuticals Business Overview
  46. 4.8.3 Modra Pharmaceuticals Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Modra Pharmaceuticals Cancer Tubulin Inhibitors Product Portfolio
  48. 4.8.5 Modra Pharmaceuticals Recent Developments
  49. 4.9 Pierre Fabre
  50. 4.9.1 Pierre Fabre Company Information
  51. 4.9.2 Pierre Fabre Business Overview
  52. 4.9.3 Pierre Fabre Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pierre Fabre Cancer Tubulin Inhibitors Product Portfolio
  54. 4.9.5 Pierre Fabre Recent Developments
  55. 4.10 Sanofi-Aventis
  56. 4.10.1 Sanofi-Aventis Company Information
  57. 4.10.2 Sanofi-Aventis Business Overview
  58. 4.10.3 Sanofi-Aventis Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sanofi-Aventis Cancer Tubulin Inhibitors Product Portfolio
  60. 4.10.5 Sanofi-Aventis Recent Developments
  61. 4.11 Seattle Genetics
  62. 4.11.1 Seattle Genetics Company Information
  63. 4.11.2 Seattle Genetics Business Overview
  64. 4.11.3 Seattle Genetics Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Seattle Genetics Cancer Tubulin Inhibitors Product Portfolio
  66. 4.11.5 Seattle Genetics Recent Developments
  67. 4.12 Tocris Bioscience
  68. 4.12.1 Tocris Bioscience Company Information
  69. 4.12.2 Tocris Bioscience Business Overview
  70. 4.12.3 Tocris Bioscience Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Tocris Bioscience Cancer Tubulin Inhibitors Product Portfolio
  72. 4.12.5 Tocris Bioscience Recent Developments
  73. 4.13 Amgen
  74. 4.13.1 Amgen Company Information
  75. 4.13.2 Amgen Business Overview
  76. 4.13.3 Amgen Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Amgen Cancer Tubulin Inhibitors Product Portfolio
  78. 4.13.5 Amgen Recent Developments
  79. 4.14 Roche
  80. 4.14.1 Roche Company Information
  81. 4.14.2 Roche Business Overview
  82. 4.14.3 Roche Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Roche Cancer Tubulin Inhibitors Product Portfolio
  84. 4.14.5 Roche Recent Developments
5 Global Cancer Tubulin Inhibitors Market Scenario by Region
  1. 5.1 Global Cancer Tubulin Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cancer Tubulin Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Cancer Tubulin Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Cancer Tubulin Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Cancer Tubulin Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Cancer Tubulin Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Cancer Tubulin Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Cancer Tubulin Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Cancer Tubulin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cancer Tubulin Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Cancer Tubulin Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Cancer Tubulin Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe Cancer Tubulin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Cancer Tubulin Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe Cancer Tubulin Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Cancer Tubulin Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Cancer Tubulin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Cancer Tubulin Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Cancer Tubulin Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Cancer Tubulin Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America Cancer Tubulin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Cancer Tubulin Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America Cancer Tubulin Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Cancer Tubulin Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Cancer Tubulin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Cancer Tubulin Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Cancer Tubulin Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Cancer Tubulin Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Cancer Tubulin Inhibitors Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Cancer Tubulin Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cancer Tubulin Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Cancer Tubulin Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cancer Tubulin Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cancer Tubulin Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cancer Tubulin Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Cancer Tubulin Inhibitors Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Cancer Tubulin Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cancer Tubulin Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Cancer Tubulin Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cancer Tubulin Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cancer Tubulin Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cancer Tubulin Inhibitors Value Chain Analysis
  2. 8.1.1 Cancer Tubulin Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cancer Tubulin Inhibitors Production Mode & Process
  5. 8.2 Cancer Tubulin Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cancer Tubulin Inhibitors Distributors
  8. 8.2.3 Cancer Tubulin Inhibitors Customers
9 Global Cancer Tubulin Inhibitors Analyzing Market Dynamics
  1. 9.1 Cancer Tubulin Inhibitors Industry Trends
  2. 9.2 Cancer Tubulin Inhibitors Industry Drivers
  3. 9.3 Cancer Tubulin Inhibitors Industry Opportunities and Challenges
  4. 9.4 Cancer Tubulin Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst